Vision Monday


Eyenovia Raises $27 Million With Initial Public Stock Offering

By Staff
Monday, February 5, 2018 12:21 AM

NEW YORK—Eyenovia Inc. (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products, reported last week that it closed its initial public offering of 2,730,000 shares of its common stock. Eyenovia said it received $27.3 million in gross proceeds from the offering, before underwriting discounts and commissions, and other estimated offering expenses. Eyenovia said it is developing eyecare products that utilize its patented piezo-print technology to deliver micro-therapeutics topically to the eye. In addition, Eyenovia said it has granted the underwriters a 30-day option to purchase up to 409,500 additional shares to cover over-allotments, if any.

Eyenovia’s common shares are traded on the Nasdaq Capital Market under the ticker symbol “EYEN.” Ladenburg Thalmann & Co. and Roth Capital Partners acted as joint book-running managers for the offering, according to the announcement.
Also Recommended
Vision Ease to Shift Poly Lens Production from Minnesota to Jakarta
J&J’s Sightbox Joins Health Care Alliance for Patient Safety
Tear Film Innovations Completes $8.5 Million Series B Funding
AmSurg Acquires Horizon Eye Specialists’ Operations in Phoenix Metro Area
Home VM Mobile